Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TX-04
- Development stage
- Unknown
- Lead developer
- Tanvex BioPharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TX-04 is a monoclonal antibody biosimilar of bevacizumab (Avastin), currently under development by Tanvex BioPharma. It is designed to target and neutralize Vascular Endothelial Growth Factor (VEGF), a key signaling protein that stimulates the formation of new blood vessels (angiogenesis). By binding to VEGF, TX-04 prevents its interaction with receptors on the surface of endothelial cells, thereby inhibiting the blood supply necessary for tumor growth and metastasis. The drug is being developed for the treatment of various solid tumors, including colorectal cancer, non-small cell lung cancer, glioblastoma, and renal cell carcinoma. As of the current pipeline status, TX-04 is in Phase 1 clinical development.
- Other names
- bevacizumab biosimilar
02
Targets
Beyond the preview
Go deeper on TX-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TX-04.